Sanara MedTech(NASDAQ) SMTI

Sanara MedTech Inc. makes medical tools for surgical procedures. These products help patients heal from wounds and bone injuries. They allow hospitals to provide better care at lower costs.

Surgical Tech and Bone Matrices

• Soft Tissue Repair: Collagen-based powders and antimicrobial solutions used to manage surgical wounds; generated $25.2 million in net revenue during the three months ended June 30, 2026.
• Bone Fusion Products: Osteoconductive matrices and allografts designed to help bones grow together after surgery; generated $2.9 million in net revenue for the three months ended June 30, 2026.
• Irrigation Solutions: Sterile no-rinse cleansers used by surgeons to remove debris and microorganisms from operative sites.
• CellerateRX Surgical: Flagship hydrolyzed collagen product sterilized and packaged specifically for use in operating rooms.
• Tissue Repair Grafts: Multilayer sheets used to reinforce soft tissue during reconstructive procedures.

Strategic Consolidation and Future Mergers

• Entered into a merger agreement with MiMedx Group on July 29, 2026, to become a wholly owned subsidiary.
• Discontinued the Tissue Health Plus value-based care initiative in Sept. 2025 to focus exclusively on surgical products.
• Awarded an Innovative Technology contract by Vizient for the BIASURGE irrigation solution on Jan. 7, 2026.
• Terminated an exclusive license agreement with Tufts University for collagen peptides effective April 20, 2026.
• Reduced a contingent liability related to the Applied Asset Purchase to zero on March 31, 2026.

Operational Strength in the Lab

Sanara utilizes an internal research and development team to create products that support its prepare, promote, and protect surgical strategy. The company reaches healthcare facilities across the United States through an independent distribution network.

Recent Financial Performance

• Net revenue reached $28.1 million in the three months ended June 30, 2026, up 9% year over year.
• Adjusted EBITDA, a non-GAAP figure, was $9.3 million for the six months ended June 30, 2026.
• Cash and cash equivalents totaled $15.4 million as of June 30, 2026.
• Principal outstanding under the CRG Term Loan was $46.5 million on June 30, 2026.

Evolution and Future Focus

Sanara has transitioned from a multi-industry healthcare firm into a specialized provider of surgical wound and bone technologies. This shift to high-margin products and the pending merger with MiMedx Group define its current strategic direction.